Key Highlights
- Baseimmune closes $11.3 million Series A funding to accelerate its novel vaccine technology, led by MSD Global Health Innovation Fund and IQ Capital.
- Funding to boost development of vaccine candidates for African swine fever, coronavirus, and malaria, alongside technology advancement and team expansion.
- Baseimmune’s proprietary AI algorithm aims to create universal “future-proof” vaccines, shortening the development time by predicting pathogen mutations.
Source: Business Wire
Notable Quotes
- “We’re thrilled to have the support of a top-tier investor syndicate… This funding will enable us to accelerate the development of our technology,” – Joshua Blight, CEO & Co-Founder at Baseimmune
- “We believe Baseimmune’s technology marks a significant advancement in proactive, adaptable vaccine solutions,” – David M. Rubin, Managing Director at MSD Global Health Innovation Fund
- “We are excited to announce our strategic investment in Baseimmune, a cutting-edge biotech leveraging AI to innovate vaccine therapies,” – Alex Wilson, Partner at IQ Capital
SoHC's Take
Baseimmune’s innovative approach represents a significant shift in the landscape of vaccine development. By leveraging deep learning AI to predict future pathogen mutations, the company is not only accelerating the creation of vaccine candidates but also ensuring these vaccines remain effective against emerging variants. This technology has the potential to dramatically change how we prepare for future pandemics, moving from reactive to proactive strategies. The successful Series A funding round underscores the confidence investors have in Baseimmune’s vision and technology, marking a pivotal moment in the pursuit of more resilient global health defenses against infectious diseases.
